IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study.
Identifieur interne : 001101 ( Ncbi/Merge ); précédent : 001100; suivant : 001102IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study.
Auteurs : Sarah Shalhoub [Oman] ; Fayssal Farahat [Arabie saoudite] ; Abdullah Al-Jiffri [Arabie saoudite] ; Raed Simhairi [Arabie saoudite] ; Omar Shamma [Arabie saoudite] ; Nauman Siddiqi [Arabie saoudite] ; Adnan Mushtaq [Arabie saoudite]Source :
- The Journal of antimicrobial chemotherapy [ 1460-2091 ] ; 2015.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Antiviraux (administration et posologie), Association de médicaments (), Charge virale, Coronavirus du syndrome respiratoire du Moyen-Orient (isolement et purification), Femelle, Humains, Infections à coronavirus (traitement médicamenteux), Interféron alpha (administration et posologie), Interféron bêta (administration et posologie), Mâle, Plasma sanguin (virologie), Pneumopathie virale (traitement médicamenteux), Poumon (virologie), Ribavirine (administration et posologie), Réaction de polymérisation en chaine en temps réel, Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus, Études rétrospectives.
- MESH :
- administration et posologie : Antiviraux, Interféron alpha, Interféron bêta, Ribavirine.
- isolement et purification : Coronavirus du syndrome respiratoire du Moyen-Orient.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- virologie : Plasma sanguin, Poumon.
- Adulte, Adulte d'âge moyen, Association de médicaments, Charge virale, Femelle, Humains, Mâle, Réaction de polymérisation en chaine en temps réel, Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus, Études rétrospectives.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Antiviral Agents (administration & dosage), Coronavirus Infections (drug therapy), Drug Therapy, Combination (methods), Female, Humans, Interferon-alpha (administration & dosage), Interferon-beta (administration & dosage), Lung (virology), Male, Middle Aged, Middle East Respiratory Syndrome Coronavirus (isolation & purification), Plasma (virology), Pneumonia, Viral (drug therapy), Real-Time Polymerase Chain Reaction, Retrospective Studies, Ribavirin (administration & dosage), Treatment Outcome, Viral Load.
- MESH :
- chemical , administration & dosage : Antiviral Agents, Interferon-alpha, Interferon-beta, Ribavirin.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- isolation & purification : Middle East Respiratory Syndrome Coronavirus.
- methods : Drug Therapy, Combination.
- virology : Lung, Plasma.
- Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Real-Time Polymerase Chain Reaction, Retrospective Studies, Treatment Outcome, Viral Load.
Abstract
Middle East respiratory syndrome coronavirus (MERS-CoV) is associated with significant mortality. We examined the utility of plasma MERS-CoV PCR as a prognostic indicator and compared the efficacies of IFN-α2a and IFN-β1a when combined with ribavirin in reducing MERS-CoV-related mortality rates.
DOI: 10.1093/jac/dkv085
PubMed: 25900158
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001640
- to stream PubMed, to step Curation: 001640
- to stream PubMed, to step Checkpoint: 001524
Links to Exploration step
pubmed:25900158Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study.</title><author><name sortKey="Shalhoub, Sarah" sort="Shalhoub, Sarah" uniqKey="Shalhoub S" first="Sarah" last="Shalhoub">Sarah Shalhoub</name><affiliation wicri:level="1"><nlm:affiliation>Infectious Diseases Division, Department of Medicine, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia sarah.shalhoub@googlemail.com.</nlm:affiliation><country wicri:rule="url">Oman</country><wicri:regionArea>Infectious Diseases Division, Department of Medicine, King Fahad Armed Forces Hospital, Jeddah</wicri:regionArea><wicri:noRegion>Jeddah</wicri:noRegion></affiliation></author><author><name sortKey="Farahat, Fayssal" sort="Farahat, Fayssal" uniqKey="Farahat F" first="Fayssal" last="Farahat">Fayssal Farahat</name><affiliation wicri:level="1"><nlm:affiliation>King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), King Abdullah International Medical Research Center (KAIMRC), Infection Prevention and Control, King Abdulaziz Medical City, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), King Abdullah International Medical Research Center (KAIMRC), Infection Prevention and Control, King Abdulaziz Medical City</wicri:regionArea><wicri:noRegion>King Abdulaziz Medical City</wicri:noRegion></affiliation></author><author><name sortKey="Al Jiffri, Abdullah" sort="Al Jiffri, Abdullah" uniqKey="Al Jiffri A" first="Abdullah" last="Al-Jiffri">Abdullah Al-Jiffri</name><affiliation wicri:level="1"><nlm:affiliation>Infection Prevention and Control, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Infection Prevention and Control, King Fahad Armed Forces Hospital, Jeddah</wicri:regionArea><wicri:noRegion>Jeddah</wicri:noRegion></affiliation></author><author><name sortKey="Simhairi, Raed" sort="Simhairi, Raed" uniqKey="Simhairi R" first="Raed" last="Simhairi">Raed Simhairi</name><affiliation wicri:level="1"><nlm:affiliation>Microbiology Laboratory, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Microbiology Laboratory, King Fahad Armed Forces Hospital, Jeddah</wicri:regionArea><wicri:noRegion>Jeddah</wicri:noRegion></affiliation></author><author><name sortKey="Shamma, Omar" sort="Shamma, Omar" uniqKey="Shamma O" first="Omar" last="Shamma">Omar Shamma</name><affiliation wicri:level="1"><nlm:affiliation>Department of Critical Care, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Department of Critical Care, King Fahad Armed Forces Hospital, Jeddah</wicri:regionArea><wicri:noRegion>Jeddah</wicri:noRegion></affiliation></author><author><name sortKey="Siddiqi, Nauman" sort="Siddiqi, Nauman" uniqKey="Siddiqi N" first="Nauman" last="Siddiqi">Nauman Siddiqi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Nephrology, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Department of Nephrology, King Fahad Armed Forces Hospital, Jeddah</wicri:regionArea><wicri:noRegion>Jeddah</wicri:noRegion></affiliation></author><author><name sortKey="Mushtaq, Adnan" sort="Mushtaq, Adnan" uniqKey="Mushtaq A" first="Adnan" last="Mushtaq">Adnan Mushtaq</name><affiliation wicri:level="1"><nlm:affiliation>Infectious Diseases Division, Department of Medicine, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Infectious Diseases Division, Department of Medicine, King Fahad Armed Forces Hospital, Jeddah</wicri:regionArea><wicri:noRegion>Jeddah</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25900158</idno><idno type="pmid">25900158</idno><idno type="doi">10.1093/jac/dkv085</idno><idno type="wicri:Area/PubMed/Corpus">001640</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001640</idno><idno type="wicri:Area/PubMed/Curation">001640</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001640</idno><idno type="wicri:Area/PubMed/Checkpoint">001524</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001524</idno><idno type="wicri:Area/Ncbi/Merge">001101</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study.</title><author><name sortKey="Shalhoub, Sarah" sort="Shalhoub, Sarah" uniqKey="Shalhoub S" first="Sarah" last="Shalhoub">Sarah Shalhoub</name><affiliation wicri:level="1"><nlm:affiliation>Infectious Diseases Division, Department of Medicine, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia sarah.shalhoub@googlemail.com.</nlm:affiliation><country wicri:rule="url">Oman</country><wicri:regionArea>Infectious Diseases Division, Department of Medicine, King Fahad Armed Forces Hospital, Jeddah</wicri:regionArea><wicri:noRegion>Jeddah</wicri:noRegion></affiliation></author><author><name sortKey="Farahat, Fayssal" sort="Farahat, Fayssal" uniqKey="Farahat F" first="Fayssal" last="Farahat">Fayssal Farahat</name><affiliation wicri:level="1"><nlm:affiliation>King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), King Abdullah International Medical Research Center (KAIMRC), Infection Prevention and Control, King Abdulaziz Medical City, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), King Abdullah International Medical Research Center (KAIMRC), Infection Prevention and Control, King Abdulaziz Medical City</wicri:regionArea><wicri:noRegion>King Abdulaziz Medical City</wicri:noRegion></affiliation></author><author><name sortKey="Al Jiffri, Abdullah" sort="Al Jiffri, Abdullah" uniqKey="Al Jiffri A" first="Abdullah" last="Al-Jiffri">Abdullah Al-Jiffri</name><affiliation wicri:level="1"><nlm:affiliation>Infection Prevention and Control, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Infection Prevention and Control, King Fahad Armed Forces Hospital, Jeddah</wicri:regionArea><wicri:noRegion>Jeddah</wicri:noRegion></affiliation></author><author><name sortKey="Simhairi, Raed" sort="Simhairi, Raed" uniqKey="Simhairi R" first="Raed" last="Simhairi">Raed Simhairi</name><affiliation wicri:level="1"><nlm:affiliation>Microbiology Laboratory, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Microbiology Laboratory, King Fahad Armed Forces Hospital, Jeddah</wicri:regionArea><wicri:noRegion>Jeddah</wicri:noRegion></affiliation></author><author><name sortKey="Shamma, Omar" sort="Shamma, Omar" uniqKey="Shamma O" first="Omar" last="Shamma">Omar Shamma</name><affiliation wicri:level="1"><nlm:affiliation>Department of Critical Care, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Department of Critical Care, King Fahad Armed Forces Hospital, Jeddah</wicri:regionArea><wicri:noRegion>Jeddah</wicri:noRegion></affiliation></author><author><name sortKey="Siddiqi, Nauman" sort="Siddiqi, Nauman" uniqKey="Siddiqi N" first="Nauman" last="Siddiqi">Nauman Siddiqi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Nephrology, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Department of Nephrology, King Fahad Armed Forces Hospital, Jeddah</wicri:regionArea><wicri:noRegion>Jeddah</wicri:noRegion></affiliation></author><author><name sortKey="Mushtaq, Adnan" sort="Mushtaq, Adnan" uniqKey="Mushtaq A" first="Adnan" last="Mushtaq">Adnan Mushtaq</name><affiliation wicri:level="1"><nlm:affiliation>Infectious Diseases Division, Department of Medicine, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Infectious Diseases Division, Department of Medicine, King Fahad Armed Forces Hospital, Jeddah</wicri:regionArea><wicri:noRegion>Jeddah</wicri:noRegion></affiliation></author></analytic><series><title level="j">The Journal of antimicrobial chemotherapy</title><idno type="eISSN">1460-2091</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antiviral Agents (administration & dosage)</term><term>Coronavirus Infections (drug therapy)</term><term>Drug Therapy, Combination (methods)</term><term>Female</term><term>Humans</term><term>Interferon-alpha (administration & dosage)</term><term>Interferon-beta (administration & dosage)</term><term>Lung (virology)</term><term>Male</term><term>Middle Aged</term><term>Middle East Respiratory Syndrome Coronavirus (isolation & purification)</term><term>Plasma (virology)</term><term>Pneumonia, Viral (drug therapy)</term><term>Real-Time Polymerase Chain Reaction</term><term>Retrospective Studies</term><term>Ribavirin (administration & dosage)</term><term>Treatment Outcome</term><term>Viral Load</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Antiviraux (administration et posologie)</term><term>Association de médicaments ()</term><term>Charge virale</term><term>Coronavirus du syndrome respiratoire du Moyen-Orient (isolement et purification)</term><term>Femelle</term><term>Humains</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Interféron alpha (administration et posologie)</term><term>Interféron bêta (administration et posologie)</term><term>Mâle</term><term>Plasma sanguin (virologie)</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Poumon (virologie)</term><term>Ribavirine (administration et posologie)</term><term>Réaction de polymérisation en chaine en temps réel</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Études rétrospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiviral Agents</term><term>Interferon-alpha</term><term>Interferon-beta</term><term>Ribavirin</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antiviraux</term><term>Interféron alpha</term><term>Interféron bêta</term><term>Ribavirine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Therapy, Combination</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Plasma sanguin</term><term>Poumon</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Lung</term><term>Plasma</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Real-Time Polymerase Chain Reaction</term><term>Retrospective Studies</term><term>Treatment Outcome</term><term>Viral Load</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Association de médicaments</term><term>Charge virale</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Réaction de polymérisation en chaine en temps réel</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Études rétrospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Middle East respiratory syndrome coronavirus (MERS-CoV) is associated with significant mortality. We examined the utility of plasma MERS-CoV PCR as a prognostic indicator and compared the efficacies of IFN-α2a and IFN-β1a when combined with ribavirin in reducing MERS-CoV-related mortality rates.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25900158</PMID><DateCompleted><Year>2016</Year><Month>03</Month><Day>11</Day></DateCompleted><DateRevised><Year>2015</Year><Month>06</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2091</ISSN><JournalIssue CitedMedium="Internet"><Volume>70</Volume><Issue>7</Issue><PubDate><Year>2015</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The Journal of antimicrobial chemotherapy</Title><ISOAbbreviation>J. Antimicrob. Chemother.</ISOAbbreviation></Journal><ArticleTitle>IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study.</ArticleTitle><Pagination><MedlinePgn>2129-32</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jac/dkv085</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Middle East respiratory syndrome coronavirus (MERS-CoV) is associated with significant mortality. We examined the utility of plasma MERS-CoV PCR as a prognostic indicator and compared the efficacies of IFN-α2a and IFN-β1a when combined with ribavirin in reducing MERS-CoV-related mortality rates.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We retrospectively analysed 32 patients with confirmed MERS-CoV infection, admitted between April 2014 and June 2014, by positive respiratory sample RT-PCR. Plasma MERS-CoV RT-PCR was performed at the time of diagnosis for 19 patients.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The overall mortality rate was 69% (22/32). Ninety percent (9/10) of patients with positive plasma MERS-CoV PCR died compared with 44% (4/9) of those with negative plasma MERS-CoV PCR. Mortality rate in patients who received IFN-α2a was 85% (11/13) compared with 64% (7/11) in those who received IFN-β1a (P = 0.24). The mortality rate in patients with renal failure (14), including 8 on haemodialysis, was 100%. Age >50 years and diabetes mellitus were found to be significantly associated with mortality (OR = 26.1; 95% CI 3.58-190.76; P = 0.001 and OR = 15.74; 95% CI 2.46-100.67; P = 0.004, respectively). The median duration of viral shedding in patients who recovered was 11 days (range 6-38 days). Absence of fever was noted in 5/32 patients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Plasma MERS-CoV RT-PCR may serve as an effective tool to predict MERS-CoV-associated mortality. Older age and comorbid conditions may have contributed to the lack of efficacy of IFN-α2a or IFN-β1a with ribavirin in treating MERS-CoV. Absence of fever should not exclude MERS-CoV.</AbstractText><CopyrightInformation>© The Author 2015. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shalhoub</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Infectious Diseases Division, Department of Medicine, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia sarah.shalhoub@googlemail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farahat</LastName><ForeName>Fayssal</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), King Abdullah International Medical Research Center (KAIMRC), Infection Prevention and Control, King Abdulaziz Medical City, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Jiffri</LastName><ForeName>Abdullah</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Infection Prevention and Control, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simhairi</LastName><ForeName>Raed</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Microbiology Laboratory, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shamma</LastName><ForeName>Omar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Critical Care, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siddiqi</LastName><ForeName>Nauman</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Nephrology, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mushtaq</LastName><ForeName>Adnan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Infectious Diseases Division, Department of Medicine, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>04</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Antimicrob Chemother</MedlineTA><NlmUniqueID>7513617</NlmUniqueID><ISSNLinking>0305-7453</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>49717AWG6K</RegistryNumber><NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance></Chemical><Chemical><RegistryNumber>77238-31-4</RegistryNumber><NameOfSubstance UI="D016899">Interferon-beta</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016899" MajorTopicYN="N">Interferon-beta</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065207" MajorTopicYN="N">Middle East Respiratory Syndrome Coronavirus</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010949" MajorTopicYN="N">Plasma</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060888" MajorTopicYN="N">Real-Time Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">MERS-CoV</Keyword><Keyword MajorTopicYN="N">interferon</Keyword><Keyword MajorTopicYN="N">treatment</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>12</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>03</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25900158</ArticleId><ArticleId IdType="pii">dkv085</ArticleId><ArticleId IdType="doi">10.1093/jac/dkv085</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Arabie saoudite</li><li>Oman</li></country></list><tree><country name="Oman"><noRegion><name sortKey="Shalhoub, Sarah" sort="Shalhoub, Sarah" uniqKey="Shalhoub S" first="Sarah" last="Shalhoub">Sarah Shalhoub</name></noRegion></country><country name="Arabie saoudite"><noRegion><name sortKey="Farahat, Fayssal" sort="Farahat, Fayssal" uniqKey="Farahat F" first="Fayssal" last="Farahat">Fayssal Farahat</name></noRegion><name sortKey="Al Jiffri, Abdullah" sort="Al Jiffri, Abdullah" uniqKey="Al Jiffri A" first="Abdullah" last="Al-Jiffri">Abdullah Al-Jiffri</name><name sortKey="Mushtaq, Adnan" sort="Mushtaq, Adnan" uniqKey="Mushtaq A" first="Adnan" last="Mushtaq">Adnan Mushtaq</name><name sortKey="Shamma, Omar" sort="Shamma, Omar" uniqKey="Shamma O" first="Omar" last="Shamma">Omar Shamma</name><name sortKey="Siddiqi, Nauman" sort="Siddiqi, Nauman" uniqKey="Siddiqi N" first="Nauman" last="Siddiqi">Nauman Siddiqi</name><name sortKey="Simhairi, Raed" sort="Simhairi, Raed" uniqKey="Simhairi R" first="Raed" last="Simhairi">Raed Simhairi</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001101 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001101 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:25900158
|texte= IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:25900158" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |